Functional and biochemical analysis of angiotensin II-forming pathways in the human heart

Circulation Research

Volumn 80, Issue 2, 1997, Pages 219-227

  Wolny, Arlene ^a   Clozel, Jean Paul ^a   Rein, Josiane ^a   Mory, Paul ^a   Vogt, Paul ^a   Turino, Marko ^a   Kiowski, Wolfgang ^a   Fischli, Walter ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

angiotensin converting enzyme; chymase; heart failure; RAS blockade

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; CHYMASE; CHYMOSTATIN; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IODINE 125; LOSARTAN; SERINE PROTEINASE INHIBITOR; SOYBEAN TRYPSIN INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HEART FAILURE; HEART VENTRICLE; HUMAN; HUMAN TISSUE; ISOLATED ARTERY; MALE; PRIORITY JOURNAL; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0031017144     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.80.2.219     Document Type: Article

References (48)

1. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev. 1977;57:313-317.
2. Lindpaintner K, Wilhelm MJ, Jin M, Unger T, Lang RE, Schoelkens BA, Ganten D. Tissue renin-angiotensin systems: focus on the heart. J Hypertens Suppl. 1987;5:S33-S38.
3. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions; the SOLVD investigators. N Engl J Med, 1992;327:685-691.
4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD investigators, N Engl J Med. 1991;325:293-302.
5. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med. 1988;319:1517-1556.
6. Materson BJ, Preston RA, Angiotensin-converting enzyme inhibitors in hypertension: a dozen years of experience. Arch Intern Med, 1994; 154:513-523.
7. Pfeffer MA, Braunwald E. Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction; results of the survival and ventricular enlargement trial: the SAVE investigators. N Engl J Med. 1992;327:669-677.
8. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H, Antihypertensive therapy with MK 421: angiotensin-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966-972.
9. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension. 1987;9:III42-III48.
10. el-Amrani AI, Menard J, Gonzalcs MF, Michel JB. Effects of blocking the angiotensin II receptor, converting enzyme, end renin activity on the renal hemodynamics of normotensive guinea pigs. J Cardiovasc Pharmacol. 1993;22:231-239.
11. Hollenberg NK, Fisher ND. Renal circulation and blockade of the renin-angiotensin system: is angiotensin-converting enzyme inhibition the last word? Hypertension. 1995,26:602-609.
12. Azizi M, Chatellier G, Guyene TT, Murieta Geoffroy D, Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995;92:825-834.
13. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin H-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
14. Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus FM, Graham RM, Husain A. Cloning of the gene and cDNA for human heart chymase. J Biol Chem. 1991;266:17173-17179.
15. Kinoshita A, Urata H, Bumpus FM, Husain A. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J Biol Chem. 1991;266:19192-19197.
16. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens Suppl. 1994;12:S17-S22.
17. Urata H. Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin invest. 1993;91:1269-1281.
18. Cornish KG, Joyner WL, Gilmore JP. Direct evidence for the presence of a different converting enzyme in the hamster cheek pouch. Circ Res. 1979;44:540-544.
19. Bumpus FM. Angiotensin I and II: some early observations made at the Cleveland Clinic Foundation and recent discoveries relative to angiotensin II formation in human heart. Hypertension. 1991;18:III-122-III-125.
20. Lindberg BF, Nilsson LG, Hedlund H, Stahl M, Andersson KE. Angiotensin I is converted to angiotensin II by a serine protease in human detrusor smooth muscle. Am J Physiol. 1994;266;R1861-R1867.
21. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol. 1993;62:207-210.
22. Miura S, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M, Tanaka H, Shindo M, Arakawa K. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens. 1994; 12:1177-1181.
23. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, Roden RL, Peacock SJ, Groves BM, Reynolds MV. Angiotensin II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway. J Clin Invest. 1995;96:1490-1498.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
25. Cushman DW, Cheung HS. Concentrations of angiotensin converting enzyme in tissue of the rat. Biochim Biophys Acta. 1971;250:261-265.
26. Nussberger J, Brunner DB, Waeber B, Brunner HR. Specific measurement of angiotensin metabolites and in vitro generated angtotensin II in plasma. Hypertension. 1986,8:476-482.
27. Toda N. Isolated human coronary arteries in response to vasoconstrictor substances. Am J Physiol. 1983;245:H937-H941.
28. Hoit BD, Shao Y, Kinoshita A, Gabel M, Husain A, Walsh RA. Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J Clin Invest. 1995;95:1519-1527
29. Ehlers MR, Riordan JF. Angiotensin-converting enzyme: new concepts concerning its biological role. Biochemistry. 1989;28:5311-5318.
30. Gavras H. Corcoran lecture: angiotensin-converting enzyme inhibition and the heart. Hypertension. 1994,23:813-818.
31. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction Nature. 1992;359:641-644.
32. Dostal DE, Baker KM. Evidence for a role of an intracardiac reninangiotensin system in normal and failing hearts. Trends Cardiovasc Med. 1993;3:67-74.
33. Rousseau MF, Konstam MA, Benedict CR, Donckier J, Galanti L, Melin J, Kinan D, Ahn S, Ketelslegers JM, Pouleur H. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol. 1994;73:488-493.
34. Hirsch AT, Talsness CE, Smith AD, Schunkert H, Ingelfinger JR, Dzau VJ. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation. 1992;86:1566-1574.
35. Squire IB, Macfadyen RJ, Reid JL, Devlin A, Lees KR. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. J Cardiovasc Pharmacol. 1996;27:657-666.
36. Kinoshita A, Urata H, Bumpus FM, Husain A. Measurement of angiotensin I convening enzyme inhibition in the heart. Circ Res. 1993; 73:51-60.
37. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun. 1987;149:1186-1192.
38. Admiraal PJ, Derkx FH, Danser AH, Pieterman H, Schalekamp MA. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension. 1990;15:44-55.
39. Sporn LA, Marder VJ, Wagner DD. Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells. J Cell Biol. 1989;108:1283-1289.
40. Urabe Y, Ideishi M. Sasaguri M, Ikeda M, Arakawa K. Beneficial effects of a serine protease inhibitor in peripheral vascular disease. Am J Cardiol. 1993;72:218-222
41. Gondo M, Maruta H, Arakawa K. Direct formation of angiotensin II without renin or converting enzyme in the ischemic dog heart. Jpn Heart J. 1989;30:219-229.
42. Brilla CG, Maisch B, Weber KT. Renin-angiotensin system and myocardial collagen matrix in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. Clin Invest. 1993;5:S35-S41.
43. Shiota N, Okunishi H, Fukamizu A, Sakonjo H, Kikumori M, Nishimura T, Nakagawa T, Murakami K, Miyazaki M. Activation of two angiotensin-generating systems in the balloon-injured artery. FEBS Lett. 1993;323:239-242.
44. Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, Clowes AW, Harker LA. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension. 1991;18:II-70-II-76.
45. Lam JY, Lacoste L, Bourassa MG. Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries. Circulation. 1992;85:1542-1547.
46. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989; 245:186-188.
47. Clozel JP, Hess P, Michael C, Schietinger K, Baumgartner HR. Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs, Hypertension. 1991;18:II-55-II-59
48. Okunishi H, Shiota N, Fukamizu A. Angiotensin antagonist, not ACE inhibitor, prevents neointimal formation on injured canine arteries. Hypertension. 1994;12:S132, Abstract.